Functional recovery results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE)
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F13%3A10210262" target="_blank" >RIV/00216208:11110/13:10210262 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00064165:_____/13:10210262
Výsledek na webu
<a href="http://dx.doi.org/10.1017/neu.2013.7" target="_blank" >http://dx.doi.org/10.1017/neu.2013.7</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1017/neu.2013.7" target="_blank" >10.1017/neu.2013.7</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Functional recovery results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE)
Popis výsledku v původním jazyce
Objective ConstaTRE is an open-label, randomised, controlled, relapse prevention trial in patients with stable schizophrenia or schizoaffective disorder switched to risperidone long-acting injectable (RLAI) or oral quetiapine, and was designed to test the hypothesis that injectable antipsychotic treatment with risperidone would be more effective than oral therapy with quetiapine. Here we report the functional recovery results from the ConstaTRE trial. Methods Clinically stable adults previously treatedwith oral risperidone, olanzapine, or oral first-generation antipsychotics were randomised to RLAI or quetiapine for 24 months. Functional recovery was assessed using the Social and Occupational Functioning Assessment Scale (SOFAS) and two quality-of-life (QoL) measures [Medical Outcomes Survey Short Form-12 (SF-12) and Schizophrenia Quality-of-Life Scale Revision 4 (SQLS-R4)]. Results A total of 666 patients were randomised and treated with RLAI (n = 329) or quetiapine (n = 337). Relaps
Název v anglickém jazyce
Functional recovery results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE)
Popis výsledku anglicky
Objective ConstaTRE is an open-label, randomised, controlled, relapse prevention trial in patients with stable schizophrenia or schizoaffective disorder switched to risperidone long-acting injectable (RLAI) or oral quetiapine, and was designed to test the hypothesis that injectable antipsychotic treatment with risperidone would be more effective than oral therapy with quetiapine. Here we report the functional recovery results from the ConstaTRE trial. Methods Clinically stable adults previously treatedwith oral risperidone, olanzapine, or oral first-generation antipsychotics were randomised to RLAI or quetiapine for 24 months. Functional recovery was assessed using the Social and Occupational Functioning Assessment Scale (SOFAS) and two quality-of-life (QoL) measures [Medical Outcomes Survey Short Form-12 (SF-12) and Schizophrenia Quality-of-Life Scale Revision 4 (SQLS-R4)]. Results A total of 666 patients were randomised and treated with RLAI (n = 329) or quetiapine (n = 337). Relaps
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FL - Psychiatrie, sexuologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Ostatní
Rok uplatnění
2013
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Acta Neuropsychiatrica [online]
ISSN
1601-5215
e-ISSN
—
Svazek periodika
25
Číslo periodika v rámci svazku
5
Stát vydavatele periodika
AR - Argentinská republika
Počet stran výsledku
10
Strana od-do
297-306
Kód UT WoS článku
000330359700007
EID výsledku v databázi Scopus
—